Key facts for NCD 190.34
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- 1,150 covered ICD-10
- 233 non-covered
TL;DR
NCD 190.34 sets Medicare's national policy for fecal occult blood test under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • To evaluate known or suspected alimentary tract conditions that might cause bleeding into the intestinal tract. As a laboratory NCD it carries a national ICD-10 edit list: 1,150 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.
Item or service described
The fecal occult blood test (FOBT) detects the presence of trace amounts of blood in stool. The procedure is performed by testing one or several small samples of one, two or three different stool specimens.
This test may be performed with or without evidence of iron deficiency anemia, which may be related to gastrointestinal blood loss. The range of causes for blood loss include inflammatory causes, including acid-peptic disease, non-steroidal anti-inflammatory drug use, hiatal hernia, Crohn's disease, ulcerative colitis, gastroenteritis, strongyloides, ascariasis, tuberculosis, and enteroamebiasis. Vascular causes include angiodysplasia, hemangiomas, varices, blue rubber bleb nevus syndrome, and watermelon stomach. Tumors and neoplastic causes include lymphoma, leiomyosarcoma, lipomas, adenocarcinoma and primary and secondary metastases to the GI tract. Drugs such as nonsteroidal anti-inflammatory drugs also cause bleeding. There are extra gastrointestinal causes such as hemoptysis, epistaxis, and oropharyngeal bleeding. Artifactual causes include hematuria, and menstrual bleeding. In addition, there may be other causes such as coagulopathies, gastrostomy tubes or other appliances, factitial causes, and long distance running.
Three basic types of fecal hemoglobin assays exist, each directed at a different component of the hemoglobin molecule.
• Immunoassays recognize antigenic sites on the globin portion and are least affected by diet or proximal gut bleeding, but the antigen may be destroyed by fecal flora.
• The heme-porphyrin assay measures heme-derived porphyrin and is least influenced by enterocolic metabolism or fecal storage. This assay does not discriminate dietary from endogenous heme. The capacity to detect proximal gut bleeding reduces its specificity for colorectal cancer screening but makes it more useful for evaluating overall GI bleeding in case finding for iron deficiency anemia.
• The guaiac-based test is the most widely used. It requires the peroxidase activity of an intact heme moiety to be reactive. Positivity rates fall with storage. Fecal hydration such as adding a drop of water increases the test reactivity but also increases false positivity.
Of these three tests, the guaiac-based test is the most sensitive for detecting lower bowel bleeding. Because of this sensitivity, it is advisable, when it is used for screening, to defer the guaiac-based test if other studies of the colon are performed prior to the test. Similarly, this test's sensitivity may result in a false positive if the patient has recently ingested meat. Both of these cautions are appropriate when the test is used for screening, but when appropriate indications are present, the test should be done despite its limitations.
Indications and limitations of coverage
Indications
• To evaluate known or suspected alimentary tract conditions that might cause bleeding into the intestinal tract.
• To evaluate unexpected anemia.
• To evaluate abnormal signs, symptoms, or complaints that might be associated with loss of blood.
• To evaluate patient complaints of black or red-tinged stools.
Limitations
• The FOBT is reported once for the testing of up to three separate specimens (comprising either one or two tests per specimen).
• In patients who are taking non-steroidal anti-inflammatory drugs and have a history of gastrointestinal bleeding but no other signs, symptoms, or complaints associated with gastrointestinal blood loss, testing for occult blood may generally be appropriate no more than once every three months.
When testing is done for the purpose of screening for colorectal cancer in the absence of signs, symptoms, conditions, or complaints associated with gastrointestinal blood loss, report the HCPCS code for colorectal cancer screening; fecal-occult blood test, 1-3 simultaneous determinations should be used.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.34 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 1,150 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 82272 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $4.23, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 82272 | $4.23 | — | national payment amount |
The first 40 of 1,150 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A02.0 | Salmonella enteritis | 2015-10-01 |
| A02.1 | Salmonella sepsis | 2015-10-01 |
| A03.0 | Shigellosis due to Shigella dysenteriae | 2015-10-01 |
| A03.1 | Shigellosis due to Shigella flexneri | 2015-10-01 |
| A03.2 | Shigellosis due to Shigella boydii | 2015-10-01 |
| A03.3 | Shigellosis due to Shigella sonnei | 2015-10-01 |
| A03.8 | Other shigellosis | 2015-10-01 |
| A03.9 | Shigellosis, unspecified | 2015-10-01 |
| A04.5 | Campylobacter enteritis | 2015-10-01 |
| A04.6 | Enteritis due to Yersinia enterocolitica | 2015-10-01 |
| A04.71 | Enterocolitis due to Clostridium difficile, recurrent | 2017-10-01 |
| A04.72 | Enterocolitis due to Clostridium difficile, not specified as recurrent | 2017-10-01 |
| A04.8 | Other specified bacterial intestinal infections | 2015-10-01 |
| A05.0 | Foodborne staphylococcal intoxication | 2015-10-01 |
| A05.1 | Botulism food poisoning | 2015-10-01 |
| A05.2 | Foodborne Clostridium perfringens [Clostridium welchii] intoxication | 2015-10-01 |
| A05.3 | Foodborne Vibrio parahaemolyticus intoxication | 2015-10-01 |
| A05.4 | Foodborne Bacillus cereus intoxication | 2015-10-01 |
| A05.5 | Foodborne Vibrio vulnificus intoxication | 2015-10-01 |
| A05.8 | Other specified bacterial foodborne intoxications | 2015-10-01 |
| A05.9 | Bacterial foodborne intoxication, unspecified | 2015-10-01 |
| A06.0 | Acute amebic dysentery | 2015-10-01 |
| A06.1 | Chronic intestinal amebiasis | 2015-10-01 |
| A06.2 | Amebic nondysenteric colitis | 2015-10-01 |
| A06.3 | Ameboma of intestine | 2015-10-01 |
| A06.4 | Amebic liver abscess | 2015-10-01 |
| A06.5 | Amebic lung abscess | 2015-10-01 |
| A06.6 | Amebic brain abscess | 2015-10-01 |
| A06.7 | Cutaneous amebiasis | 2015-10-01 |
| A06.81 | Amebic cystitis | 2015-10-01 |
| A06.82 | Other amebic genitourinary infections | 2015-10-01 |
| A06.89 | Other amebic infections | 2015-10-01 |
| A06.9 | Amebiasis, unspecified | 2015-10-01 |
| A07.0 | Balantidiasis | 2015-10-01 |
| A07.1 | Giardiasis [lambliasis] | 2015-10-01 |
| A07.2 | Cryptosporidiosis | 2015-10-01 |
| A07.3 | Isosporiasis | 2015-10-01 |
| A07.4 | Cyclosporiasis | 2015-10-01 |
| A07.8 | Other specified protozoal intestinal diseases | 2015-10-01 |
| A07.9 | Protozoal intestinal disease, unspecified | 2015-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 2 codes added and 1 code removed against January 2026. CMS marked 2 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.
| ICD-10-CM | FY2027 description | Result |
|---|---|---|
| D69.11 | Glanzmann thrombasthenia | covered |
| D69.19 | Other qualitative platelet defects | covered |
| ICD-10-CM | Description | Was | Why |
|---|---|---|---|
| D69.1 | Qualitative platelet defects | covered | deleted from ICD-10-CM; replaced by D69.11, D69.19 |
Codes on this NCD's list by release: October 2025: 1,379 · January 2026: 1,382 · October 2026: 1,383. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Coverage analysis history
CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 190.34, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.
- CAG-00180N Screening Immunoassay Fecal-Occult Blood Test (New, Closed)
Revision history
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.34
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.34
What does NCD 190.34 cover?
• To evaluate known or suspected alimentary tract conditions that might cause bleeding into the intestinal tract. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.34 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.34?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.34?
The October 2026 laboratory NCD edit list contains 1,150 ICD-10-CM codes that support fecal occult blood test (for example A02.0 Salmonella enteritis; A02.1 Salmonella sepsis; A03.0 Shigellosis due to Shigella dysenteriae) and 233 codes that deny. The list applies to 82272.
How often does the lab NCD code list for 190.34 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database national coverage analyses (NCA/CAL report) via the CMS Coverage APIVersion API snapshot 2026-11-16 · effective 2026-11-16 · file national-coverage-ncacal.jsonSHA-256 563369a07b95140a…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.